Drug
Rivoglitazone
Rivoglitazone: highest development phase Phase 3, developed by Daiichi Sankyo. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rivoglitazone HCl NCT00571519 | Phase 3 | Type 2 Diabetes Mellitus |
| Rivoglitazone HCl NCT00575471 | Phase 2 | Type 2 Diabetes |
| Rivoglitazone HCl NCT00575874 | Phase 2 | Type 2 Diabetes |
Latest
No recent events.
Follow Rivoglitazone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.